Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial
Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis. Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received...
Gespeichert in:
| Veröffentlicht in: | Clinical nutrition (Edinburgh, Scotland) Scotland), 2005-04, Vol.24 (2), p.198-205 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 205 |
|---|---|
| container_issue | 2 |
| container_start_page | 198 |
| container_title | Clinical nutrition (Edinburgh, Scotland) |
| container_volume | 24 |
| creator | Lasztity, Natalia Hamvas, Jozsef Biró, Lajos Németh, Éva Marosvölgyi, Tamas Decsi, Tamás Pap, Ákos Antal, Magda |
| description | Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis.
Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received n-3 PUFAs (fish oil) enterally (3.3
g/day for 5–7 days). Measurement of erythrocyte superoxide-dysmutase (SOD) activity, serum total antioxidant status (TAS), vitamin A and E, fatty acids, C-reactive protein, transthyretin concentrations were performed at admission, day 3, 7 and 14.
Results: The n-3 to n-6 LCPUFA ratios increased significantly in serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in significant decrease in length of hospitalization (13.07±6.70 vs. 19.28±7.18 days,
P
<
0.05
) and jejunal feeding (10.57±6.70 vs. 17.57±10.52,
P
<
0.05
). Complications developed in 6/14 (42%) of treated and 9/14 (64%) of control patients. The SOD activity was significantly higher at day 3 in the supplemented group (
P
<
0.05
), but there were no significant differences between the two groups in other antioxidants and acute phase reactants.
Conclusion: The use of enteral formula enriched with n-3 PUFAs in the treatment of AP seems to have clinical benefits based upon the shortened time of jejunal feeding and hospital stay. |
| doi_str_mv | 10.1016/j.clnu.2004.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67536305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0261561404002171</els_id><sourcerecordid>67536305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-e1b0e8e25292903ad4714f3f67df64e7ec101444eb5cc4d92b9cf04deb455ca53</originalsourceid><addsrcrecordid>eNp9kM2KFDEYRYMoTk_rC7iQ2uiuyvxXFbiRYXSEATe6DqnkC6RJpcokNdCu5iHmCX0S03TD7FyE_HC-y81B6B3BHcFEfjp0JsStoxjzjtAO4-EF2hHBaEvGgb1EO0wlaYUk_Apd53zAGAvWD6_RFRH9wHk_7NDjrXNgSrO4BmKBpEM4NtrOPvpcr2Cb2LJmXcJxi1mXLelS35wupWLG29z4WA9bgWbV0STQxRef_z4-6WZNS15ruH-AJulol9n_qcMm1HCjQ1OS1-ENeuV0yPD2su_Rr6-3P2_u2vsf377ffLlvDRe4tEAmDANQQUc6YqYt7wl3zMneOsmhB1OVcM5hEsZwO9JpNA5zCxMXwmjB9ujjObe2-r1BLmr22UAIOsKyZSV7wSTDJ5CeQVPr5wROrcnPOh0VwerkXR3Uybs6eVeEquq9Dr2_pG_TDPZ55CK6Ah8ugM717676MD4_c1JKxuvao89nDqqLBw9JZeMhGrA-VZXKLv5_Pf4B9nOlTQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67536305</pqid></control><display><type>article</type><title>Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lasztity, Natalia ; Hamvas, Jozsef ; Biró, Lajos ; Németh, Éva ; Marosvölgyi, Tamas ; Decsi, Tamás ; Pap, Ákos ; Antal, Magda</creator><creatorcontrib>Lasztity, Natalia ; Hamvas, Jozsef ; Biró, Lajos ; Németh, Éva ; Marosvölgyi, Tamas ; Decsi, Tamás ; Pap, Ákos ; Antal, Magda</creatorcontrib><description>Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis.
Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received n-3 PUFAs (fish oil) enterally (3.3
g/day for 5–7 days). Measurement of erythrocyte superoxide-dysmutase (SOD) activity, serum total antioxidant status (TAS), vitamin A and E, fatty acids, C-reactive protein, transthyretin concentrations were performed at admission, day 3, 7 and 14.
Results: The n-3 to n-6 LCPUFA ratios increased significantly in serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in significant decrease in length of hospitalization (13.07±6.70 vs. 19.28±7.18 days,
P
<
0.05
) and jejunal feeding (10.57±6.70 vs. 17.57±10.52,
P
<
0.05
). Complications developed in 6/14 (42%) of treated and 9/14 (64%) of control patients. The SOD activity was significantly higher at day 3 in the supplemented group (
P
<
0.05
), but there were no significant differences between the two groups in other antioxidants and acute phase reactants.
Conclusion: The use of enteral formula enriched with n-3 PUFAs in the treatment of AP seems to have clinical benefits based upon the shortened time of jejunal feeding and hospital stay.</description><identifier>ISSN: 0261-5614</identifier><identifier>EISSN: 1532-1983</identifier><identifier>DOI: 10.1016/j.clnu.2004.12.008</identifier><identifier>PMID: 15784478</identifier><identifier>CODEN: CLNUDP</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Acute Disease ; Acute pancreatitis ; Adult ; Aged ; Aged, 80 and over ; Antioxidants - metabolism ; Antioxidants - therapeutic use ; Arachidonic acid ; Biological and medical sciences ; Docosahexaenoic acid ; Enteral Nutrition ; Erythrocytes - enzymology ; Fatty Acids, Omega-3 - blood ; Fatty Acids, Omega-3 - therapeutic use ; Fatty Acids, Omega-6 - blood ; Female ; Fish Oils - therapeutic use ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Length of Stay ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; n-3 polyunsaturated fatty acids ; n-6 polyunsaturated fatty ; Other diseases. Semiology ; Pancreatitis - blood ; Pancreatitis - therapy ; Prospective Studies ; Severity of Illness Index ; Superoxide Dismutase - metabolism ; Treatment Outcome</subject><ispartof>Clinical nutrition (Edinburgh, Scotland), 2005-04, Vol.24 (2), p.198-205</ispartof><rights>2005 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-e1b0e8e25292903ad4714f3f67df64e7ec101444eb5cc4d92b9cf04deb455ca53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0261561404002171$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16663466$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15784478$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lasztity, Natalia</creatorcontrib><creatorcontrib>Hamvas, Jozsef</creatorcontrib><creatorcontrib>Biró, Lajos</creatorcontrib><creatorcontrib>Németh, Éva</creatorcontrib><creatorcontrib>Marosvölgyi, Tamas</creatorcontrib><creatorcontrib>Decsi, Tamás</creatorcontrib><creatorcontrib>Pap, Ákos</creatorcontrib><creatorcontrib>Antal, Magda</creatorcontrib><title>Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial</title><title>Clinical nutrition (Edinburgh, Scotland)</title><addtitle>Clin Nutr</addtitle><description>Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis.
Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received n-3 PUFAs (fish oil) enterally (3.3
g/day for 5–7 days). Measurement of erythrocyte superoxide-dysmutase (SOD) activity, serum total antioxidant status (TAS), vitamin A and E, fatty acids, C-reactive protein, transthyretin concentrations were performed at admission, day 3, 7 and 14.
Results: The n-3 to n-6 LCPUFA ratios increased significantly in serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in significant decrease in length of hospitalization (13.07±6.70 vs. 19.28±7.18 days,
P
<
0.05
) and jejunal feeding (10.57±6.70 vs. 17.57±10.52,
P
<
0.05
). Complications developed in 6/14 (42%) of treated and 9/14 (64%) of control patients. The SOD activity was significantly higher at day 3 in the supplemented group (
P
<
0.05
), but there were no significant differences between the two groups in other antioxidants and acute phase reactants.
Conclusion: The use of enteral formula enriched with n-3 PUFAs in the treatment of AP seems to have clinical benefits based upon the shortened time of jejunal feeding and hospital stay.</description><subject>Acute Disease</subject><subject>Acute pancreatitis</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antioxidants - metabolism</subject><subject>Antioxidants - therapeutic use</subject><subject>Arachidonic acid</subject><subject>Biological and medical sciences</subject><subject>Docosahexaenoic acid</subject><subject>Enteral Nutrition</subject><subject>Erythrocytes - enzymology</subject><subject>Fatty Acids, Omega-3 - blood</subject><subject>Fatty Acids, Omega-3 - therapeutic use</subject><subject>Fatty Acids, Omega-6 - blood</subject><subject>Female</subject><subject>Fish Oils - therapeutic use</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>n-3 polyunsaturated fatty acids</subject><subject>n-6 polyunsaturated fatty</subject><subject>Other diseases. Semiology</subject><subject>Pancreatitis - blood</subject><subject>Pancreatitis - therapy</subject><subject>Prospective Studies</subject><subject>Severity of Illness Index</subject><subject>Superoxide Dismutase - metabolism</subject><subject>Treatment Outcome</subject><issn>0261-5614</issn><issn>1532-1983</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM2KFDEYRYMoTk_rC7iQ2uiuyvxXFbiRYXSEATe6DqnkC6RJpcokNdCu5iHmCX0S03TD7FyE_HC-y81B6B3BHcFEfjp0JsStoxjzjtAO4-EF2hHBaEvGgb1EO0wlaYUk_Apd53zAGAvWD6_RFRH9wHk_7NDjrXNgSrO4BmKBpEM4NtrOPvpcr2Cb2LJmXcJxi1mXLelS35wupWLG29z4WA9bgWbV0STQxRef_z4-6WZNS15ruH-AJulol9n_qcMm1HCjQ1OS1-ENeuV0yPD2su_Rr6-3P2_u2vsf377ffLlvDRe4tEAmDANQQUc6YqYt7wl3zMneOsmhB1OVcM5hEsZwO9JpNA5zCxMXwmjB9ujjObe2-r1BLmr22UAIOsKyZSV7wSTDJ5CeQVPr5wROrcnPOh0VwerkXR3Uybs6eVeEquq9Dr2_pG_TDPZ55CK6Ah8ugM717676MD4_c1JKxuvao89nDqqLBw9JZeMhGrA-VZXKLv5_Pf4B9nOlTQ</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Lasztity, Natalia</creator><creator>Hamvas, Jozsef</creator><creator>Biró, Lajos</creator><creator>Németh, Éva</creator><creator>Marosvölgyi, Tamas</creator><creator>Decsi, Tamás</creator><creator>Pap, Ákos</creator><creator>Antal, Magda</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050401</creationdate><title>Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial</title><author>Lasztity, Natalia ; Hamvas, Jozsef ; Biró, Lajos ; Németh, Éva ; Marosvölgyi, Tamas ; Decsi, Tamás ; Pap, Ákos ; Antal, Magda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-e1b0e8e25292903ad4714f3f67df64e7ec101444eb5cc4d92b9cf04deb455ca53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acute Disease</topic><topic>Acute pancreatitis</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antioxidants - metabolism</topic><topic>Antioxidants - therapeutic use</topic><topic>Arachidonic acid</topic><topic>Biological and medical sciences</topic><topic>Docosahexaenoic acid</topic><topic>Enteral Nutrition</topic><topic>Erythrocytes - enzymology</topic><topic>Fatty Acids, Omega-3 - blood</topic><topic>Fatty Acids, Omega-3 - therapeutic use</topic><topic>Fatty Acids, Omega-6 - blood</topic><topic>Female</topic><topic>Fish Oils - therapeutic use</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>n-3 polyunsaturated fatty acids</topic><topic>n-6 polyunsaturated fatty</topic><topic>Other diseases. Semiology</topic><topic>Pancreatitis - blood</topic><topic>Pancreatitis - therapy</topic><topic>Prospective Studies</topic><topic>Severity of Illness Index</topic><topic>Superoxide Dismutase - metabolism</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lasztity, Natalia</creatorcontrib><creatorcontrib>Hamvas, Jozsef</creatorcontrib><creatorcontrib>Biró, Lajos</creatorcontrib><creatorcontrib>Németh, Éva</creatorcontrib><creatorcontrib>Marosvölgyi, Tamas</creatorcontrib><creatorcontrib>Decsi, Tamás</creatorcontrib><creatorcontrib>Pap, Ákos</creatorcontrib><creatorcontrib>Antal, Magda</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nutrition (Edinburgh, Scotland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lasztity, Natalia</au><au>Hamvas, Jozsef</au><au>Biró, Lajos</au><au>Németh, Éva</au><au>Marosvölgyi, Tamas</au><au>Decsi, Tamás</au><au>Pap, Ákos</au><au>Antal, Magda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial</atitle><jtitle>Clinical nutrition (Edinburgh, Scotland)</jtitle><addtitle>Clin Nutr</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>24</volume><issue>2</issue><spage>198</spage><epage>205</epage><pages>198-205</pages><issn>0261-5614</issn><eissn>1532-1983</eissn><coden>CLNUDP</coden><abstract>Background: In acute pancreatitis (AP) administration of n-3 polyunsaturated fatty acids (PUFAs) might change the course of the disease through modulation of eicosanoid synthesis.
Patients and Methods: In a prospective, randomized clinical trial from 28 patients with moderate-severe AP, 14 received n-3 PUFAs (fish oil) enterally (3.3
g/day for 5–7 days). Measurement of erythrocyte superoxide-dysmutase (SOD) activity, serum total antioxidant status (TAS), vitamin A and E, fatty acids, C-reactive protein, transthyretin concentrations were performed at admission, day 3, 7 and 14.
Results: The n-3 to n-6 LCPUFA ratios increased significantly in serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in significant decrease in length of hospitalization (13.07±6.70 vs. 19.28±7.18 days,
P
<
0.05
) and jejunal feeding (10.57±6.70 vs. 17.57±10.52,
P
<
0.05
). Complications developed in 6/14 (42%) of treated and 9/14 (64%) of control patients. The SOD activity was significantly higher at day 3 in the supplemented group (
P
<
0.05
), but there were no significant differences between the two groups in other antioxidants and acute phase reactants.
Conclusion: The use of enteral formula enriched with n-3 PUFAs in the treatment of AP seems to have clinical benefits based upon the shortened time of jejunal feeding and hospital stay.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>15784478</pmid><doi>10.1016/j.clnu.2004.12.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0261-5614 |
| ispartof | Clinical nutrition (Edinburgh, Scotland), 2005-04, Vol.24 (2), p.198-205 |
| issn | 0261-5614 1532-1983 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67536305 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acute Disease Acute pancreatitis Adult Aged Aged, 80 and over Antioxidants - metabolism Antioxidants - therapeutic use Arachidonic acid Biological and medical sciences Docosahexaenoic acid Enteral Nutrition Erythrocytes - enzymology Fatty Acids, Omega-3 - blood Fatty Acids, Omega-3 - therapeutic use Fatty Acids, Omega-6 - blood Female Fish Oils - therapeutic use Gastroenterology. Liver. Pancreas. Abdomen Humans Length of Stay Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Metabolic diseases Middle Aged n-3 polyunsaturated fatty acids n-6 polyunsaturated fatty Other diseases. Semiology Pancreatitis - blood Pancreatitis - therapy Prospective Studies Severity of Illness Index Superoxide Dismutase - metabolism Treatment Outcome |
| title | Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis—a prospective randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A39%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20enterally%20administered%20n-3%20polyunsaturated%20fatty%20acids%20in%20acute%20pancreatitis%E2%80%94a%20prospective%20randomized%20clinical%20trial&rft.jtitle=Clinical%20nutrition%20(Edinburgh,%20Scotland)&rft.au=Lasztity,%20Natalia&rft.date=2005-04-01&rft.volume=24&rft.issue=2&rft.spage=198&rft.epage=205&rft.pages=198-205&rft.issn=0261-5614&rft.eissn=1532-1983&rft.coden=CLNUDP&rft_id=info:doi/10.1016/j.clnu.2004.12.008&rft_dat=%3Cproquest_cross%3E67536305%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67536305&rft_id=info:pmid/15784478&rft_els_id=S0261561404002171&rfr_iscdi=true |